Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03802604
Title Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications

triple-receptor negative breast cancer

breast adenocarcinoma

Therapies

Atezolizumab + Talimogene laherparepvec

Age Groups: senior | adult
Covered Countries ESP


No variant requirements are available.